LUCIDITY Study – Protocol Amendment

Jul 20 - 2018 06:03 PM
TauRx Therapeutics Ltd has announced that it has revised the design of its LUCIDITY clinical study (Study TRx-237-039) in light of new guidance issued by the FDA
Read more

Alzheimer candidate LMTX® inhibits α-sync aggregation in pre-clinical Parkinson’s Disease study

Jan 25 - 2018 03:20 PM
TauRx Therapeutics Ltd has reported preclinical study results, published online in Frontiers in Molecular Neuroscience
Read more

Second Phase 3 Study Results for LMTX® published in the Journal of Alzheimer’s Disease

Nov 27 - 2017 12:28 PM
ABERDEEN, Scotland and Singapore, November 27, 2017 – TauRx Therapeutics Ltd today reported the full results from its second Phase 3 clinical study of LMTX®, the first tau aggregation inhibitor in Alzheimer’s disease, published online in the Journal of Alzheimer’s Disease.
Read more

TRx-237-005 Phase 3 Clinical Trial

Dec 17 - 2016 12:00 AM
Top-line results from TauRx Therapeutics Ltd.’s second Phase 3 trial in Alzheimer’s disease, study TRx-237-005, were presented at the 9th Clinical Trials on Alzheimer’s Disease (CTAD) 2016 meeting in San Diego, CA, USA.1
Read more

TRx-237-015 Publication Update

Nov 16 - 2016 11:05 AM
ABERDEEN, Scotland and Singapore, 16th November 2016 – Following presentation of top-line results from its TRx-237-015 Phase 3 clinical trial in Alzheimer’s disease at the 2016 Alzheimer’s Association International Conference (AAIC) in Toronto, Canada in July, TauRx today confirms publication of the full study results in The Lancet.
Read more